Can a Weight-Loss drug shield hearts in type 1 diabetes?

NCT ID NCT06411210

Recruiting now Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This trial is testing whether semaglutide, a medication used for obesity, can improve heart health in young adults (ages 18-30) who have both type 1 diabetes and obesity. Participants will receive either semaglutide or a placebo for a year. The study will measure changes in body fat, insulin resistance, and blood fats to see if the drug reduces cardiovascular risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Semaglutide (an injectable GLP-1 medication)
What this could lead to: If successful, this could show that semaglutide reduces heart risk in young adults with type 1 diabetes and obesity, potentially leading to a new treatment option.
What could go wrong: This is a small, early-stage trial, and results may not apply to everyone. Semaglutide can cause side effects like nausea and vomiting, and its long-term effects in type 1 diabetes are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES TYPE1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES TYPE1 OBESITY

Contacts and locations

Locations

Yale Pediatric Diabetes Center, Adult and Children's Progam
RECRUITING

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.